SeraNovo Enters into License Agreement with Équilibre BioPharmaceuticals

SeraNovo Enters into a License Agreement with Équilibre BioPharmaceuticals

Leiden, November 08th, 2021: SeraNovo Enters into License Agreement with Équilibre BioPharmaceuticals.

SeraNovo BV (Leiden, The Netherlands) is pleased to announce the closing of a License Agreement with Équilibre BioPharmaceuticals Corporation (New York, USA), a biopharmaceutical company engaged in the research and development of small molecules in the field of neuroscience. Under the agreement, the companies will expand their existing collaboration and jointly develop a breakthrough product.


Niall Hodgins, Chief Executive Officer of SeraNovo commented: “We are thrilled to enter into this license agreement with Équilibre and progress another poorly water soluble active pharmaceutical ingredient (API) into the clinic using our deep eutectic solvent formulation platform. This agreement is a great step to broaden our customer base in North America and into the neurology field. SeraNovo are looking forward to many fruitful collaborations in these important markets.” 

About SeraNovo

SeraNovo is an innovative formulation company focused on improving the bioavailability of active pharmaceutical ingredients. The focus of the company is on solving the problem of poor API solubility by designing tailor-made, deep eutectic solvent  based formulations to increase bioavailability. SeraNovo is a privately owned company located in Leiden, the Netherlands and as technology inventor owns all know-how and intellectual property.

About Équilibre

Équilibre Biopharmaceuticals Corp. is an innovative biopharmaceutical company. They are focused on identifying and developing high-potential APIs in the fields of seizure disorders, traumatic brain injury and spasticity associated with spinal cord injury. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements regarding development plans, the deep eutectic solvent Formulation Platform, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law.


For further information, please contact Niall Hodgins – CEO (